Untitled

Oosterbaan, M. J. M.; Dirks, Rita; Vree, T. B.; Kleijn, Eppo van der

doi:10.1023/a:1016378609450

Cited by 28 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2, K c ten = 1 10 ml/min for subject K.), as is the case for DX (10). The half lives of the plasma concentration and renal excretion rate curves should therefore be identical.…”

Section: Resultsmentioning

confidence: 92%

Pharmacokinetics of 4′-epi-doxorubicin in man

et al. 1983

View full text Add to dashboard Cite

The pharmacokinetics of 4'-epi-doxorubicin (4'-epi-adriamycin, 4'-epi-DX) in man can be described by a three-compartment model with a rapid distribution phase and a very long elimination phase. Urine excretion amounts to a total of about 11% of the administered dose during 48 h after drug administration, and less than 1% during the following 48 h. In plasma 4'-epi-doxorubicin is rapidly converted to five metabolites (4'-epi-doxorubicinol, aglycones and glucuronides), the concentration of the aglycones sometimes exceeding that of 4'-epi-DX. In urine only three metabolites were found in addition to the parent drug; they were identified as 4'-epi-doxorubicinol (EOH), 4'-epi-doxorubicin-glucuronide (E-Glu) and 4'-epi-doxorubicinol-glucuronide (EOH-Glu). Comparison of the pharmacokinetics and metabolic profiles of 4'-epi-DX and doxorubicin (DX) in man revealed that 4'-epi-DX eliminates faster than DX.

show abstract

“…2, K c ten = 1 10 ml/min for subject K.), as is the case for DX (10). The half lives of the plasma concentration and renal excretion rate curves should therefore be identical.…”

Section: Resultsmentioning

confidence: 92%

Pharmacokinetics of 4′-epi-doxorubicin in man

et al. 1983

View full text Add to dashboard Cite

show abstract

“…Numerous methods have been developed using high-performance liquid chromatography (HPLC) with various detectors. Traditionally, HPLC in combination with ultraviolet detection [2][3][4][5][6][7] and capillary zone electrophoresis (CZE) coupled with an amperometric detector [8] were employed to determine anthracyclines in biological fluids. However, because of these techniques suffer from low sensitivity and specificity only few quantitative methods were developed.…”

Section: Introductionmentioning

confidence: 99%

Validation of an LC–MS/MS method for the determination of epirubicin in human serum of patients undergoing Drug Eluting Microsphere-Transarterial Chemoembolization (DEM-TACE)

Sottani¹,

Leoni²,

Porro³

et al. 2009

Journal of Chromatography B

View full text Add to dashboard Cite

“…The development of an analytical method for quantifying these four analytes in the urine of people who are occupationally exposed to these antibiotics is described in this paper. A few high‐performance liquid chromatography methods with visible spectrophotometry (HPLC‐UV)4–9 have been reported for the determination of single anthracyclines, and many HPLC assays using fluorescence detection (HPLC‐FL) have recently been published 10–21. It should be noted that trace analysis at sub‐ppb levels can become feasible only if an improved detection system, such as fluorescence or mass detection (MS), is used.…”

mentioning

confidence: 99%

Trace determination of anthracyclines in urine: a new high‐performance liquid chromatography/tandem mass spectrometry method for assessing exposure of hospital personnel

Sottani

Tranfo²,

Bettinelli

et al. 2004

Rapid Comm Mass Spectrometry

View full text Add to dashboard Cite

Health-care workers handling antineoplastic agents may be exposed to extremely low doses of these drugs. Very sensitive and specific analytical methods are therefore needed for biological monitoring. The aim of this study was to develop and validate a method for trace level determination of doxorubicin, epirubicin, daunorubicin and idarubicin in human urine, using epi-daunorubicin as an internal standard. Solid-phase extraction (SPE) was used for sample preparation. Urine samples were loaded onto Bond Elut C18 cartridges. The analytes were eluted in methylene chloride/2-propanol (1:1, v/v) and then evaporated to dryness. The residue was reconstituted with the mobile phase prior to high-performance liquid chromatography/tandem mass spectrometry (HPLC/MS/MS) analysis. Quantitation of each analyte was performed using the multiple reaction monitoring (MRM) method. The urine assay was linear over the range 0.1-2.0 microg/L, with a lower limit of quantification (LLOQ) of 0.10 microg/L for doxorubicin and epirubicin, and 0.03 microg/L for daunorubicin and idarubicin. The respective limits of detection (LODs) were 0.04 and 0.01 microg/L. The precision and accuracy of the assay were determined on three different days. The within-series precision was found to be always less than 13.9% for all the analytes. The overall precision expressed as relative standard deviation (RSD) was always less than 10.6%. The recovery of anthracyclines was assessed at two concentrations of the range tested (0.1 and 2.0 microg/L) and it ranged from 87.7% (daunorubicin) to 102.0% (doxorubicin) and from 79.1% (daunorubicin) to 90.7% (idarubicin) for the lower and the higher level, respectively, with a RSD always less than 9.1%. The uncertainty of the present assay was also evaluated and the combined uncertainty was always less than 20% over all the days of the validation study. This is the first method that makes use of LC/MS/MS for the biological monitoring of occupational exposure to anthracyclines.

show abstract

Untitled

Cited by 28 publications

References 4 publications

Pharmacokinetics of 4′-epi-doxorubicin in man

Pharmacokinetics of 4′-epi-doxorubicin in man

Validation of an LC–MS/MS method for the determination of epirubicin in human serum of patients undergoing Drug Eluting Microsphere-Transarterial Chemoembolization (DEM-TACE)

Trace determination of anthracyclines in urine: a new high‐performance liquid chromatography/tandem mass spectrometry method for assessing exposure of hospital personnel

Contact Info

Product

Resources

About